Țară: Israel
Limbă: engleză
Sursă: Ministry of Health
VEDOLIZUMAB
TAKEDA ISRAEL LTD
A04AA33
SOLUTION FOR INJECTION
VEDOLIZUMAB 158.8 MG / 1 ML
S.C
Required
TAKEDA PHARMA A/S, DENMARK
VEDOLIZUMAB
Ulcerative colitisEntyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.Crohn’s diseaseEntyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.
2022-07-26
1 File Name Entyvio SC-Pen-PIL-ENG-D24 Product Entyvio Job No. 23000806 Language English Artwork Patient Leaflet Document History Ver. Date Change description By 29-Aug-23 12:22 Last save _Our Expertise. Your Success._ 2 Patient leaflet in accordance with the Pharmacists' Regulations (Preparations) - 1986 This medicine is dispensed with a doctor’s prescription only Entyvio ® S.C. Solution for subcutaneous injection in a pre-filled pen Active ingredient and its quantity: Each pre-filled pen contains 108 mg of vedolizumab in 0.68 ml solution. Inactive ingredients and allergens: See section 6 'Additional information'. Read the entire leaflet carefully before you start using this medicine. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if it seems to you that their medical condition is similar to yours. 1. What is this medicine intended for? Entyvio S.C. is used to treat the signs and symptoms in adults of : moderately to severely active ulcerative colitis . moderately to severely active Crohn’s disease . Ulcerative colitis Entyvio S.C. is indicated for treatment of adults with moderately to severely active ulcerative colitis who demonstrated inadequate response, stopped responding or exhibited intolerance to the standard of care or to tumor necrosis factor-alpha (TNFα) antagonist. Crohn’s disease Entyvio S.C. is indicated for treatment of adults with moderately to severely active Crohn’s disease who demonstrated inadequate response, stopped responding or exhibited intolerance to the standard of care or to tumor necrosis factor-alpha (TNFα) antagonist. Therapeutic group: Selective immunosuppressants (monoclonal antibodies - MAbs). Entyvio contains the active substance vedolizumab. Vedolizumab belongs to a group of biological medicines called monoclonal antibodies (MAbs). Entyvio works by blocking a protein located on the Citiți documentul complet
1 1. NAME OF THE MEDICINAL PRODUCT Entyvio SC Solution for injection in pre-filled syringe Solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Entyvio 108 mg solution for injection in pre-filled syringe Each pre-filled syringe contains 108 mg of vedolizumab in 0.68 mL. Entyvio 108 mg solution for injection in pre-filled pen Each pre-filled pen contains 108 mg of vedolizumab in 0.68 mL. Vedolizumab is a humanised IgG 1 monoclonal antibody produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Colourless to yellow solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Ulcerative colitis Entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. Crohn’s disease Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. 4.2 Posology and method of administration Treatment should be initiated and supervised by specialist healthcare professionals experienced in the diagnosis and treatment of ulcerative colitis or Crohn’s disease (see section 4.4). Patients should be given the package leaflet. 2 Posology _Ulcerative colitis and Crohn’s disease _ The recommended dose regimen of subcutaneous vedolizumab as a maintenance treatment, following at least 2 intravenous infusions, is 108 mg administered by subcutaneous injection once every 2 weeks. The first subcutaneous dose should be administered in place of the next scheduled intravenous dose and every 2 weeks thereafter. For the intravenous dose regimen, see section 4.2 of the En Citiți documentul complet